A Phase 2 Trial of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CheckMate 650
- Sponsors Bristol-Myers Squibb
- 19 Apr 2017 Planned primary completion date changed from 1 Jul 2018 to 16 Dec 2018.
- 21 Mar 2017 Status changed from not yet recruiting to recruiting.
- 07 Mar 2017 Planned End Date changed from 1 Feb 2022 to 1 Mar 2022.